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Jørgen F.P. Wojtaszewski,6 Jonas T. Treebak,7 Charles J. Tanner,2,8 and Joseph A. Houmard2,8
The purpose of this study was to determine if site-speciﬁc
phosphorylation at the level of Akt substrate of 160 kDa (AS160)
is altered in skeletal muscle from sedentary humans across
a wide range of the adult life span (18–84 years of age) and if
endurance- and/or strength-oriented exercise training could rescue
decrements in insulin action and skeletal muscle AS160 phosphor-
ylation. A euglycemic-hyperinsulinemic clamp and skeletal muscle
biopsies were performed in 73 individuals encompassing a wide
age range (18–84 years of age), and insulin-stimulated AS160 phos-
phorylation was determined. Decrements in whole-body insulin
action were associated with impairments in insulin-induced phos-
phorylation of skeletal muscle AS160 on sites Ser-588, Thr-642,
Ser-666, and phospho-Akt substrate, but not Ser-318 or Ser-751.
Twelve weeks of endurance- or strength-oriented exercise training
increased whole-body insulin action and reversed impairments in
AS160 phosphorylation evident in insulin-resistant aged individu-
als. These ﬁndings suggest that a dampening of insulin-induced
phosphorylation of AS160 on speciﬁc sites in skeletal muscle con-
tributes to the insulin resistance evident in a sedentary aging pop-
ulation and that exercise training is an effective intervention for
treating these impairments. Diabetes 62:3437–3447, 2013
Skeletal muscle plays a prominent role in whole-body glucose regulation and is considered theprimary target for insulin-mediated glucose up-take (1). In skeletal muscle, the binding of insulin
to the insulin receptor initiates a signaling process that
results in the translocation of the insulin-sensitive glucose
transporter (GLUT4) to cell surface membranes and the
facilitated diffusion of glucose into the cell (2). The com-
plex nature of this process is evident by data indicating
normal activation of proximal signaling components, in-
cluding Akt, despite overt insulin-resistant conditions
imposed by lipid infusion (3), fasting (4), obesity (5), and
diabetes (5). Such ﬁndings suggest that elements down-
stream of Akt may be more closely related to insulin action.
In skeletal muscle, the Akt substrate of 160 kDa (AS160,
also known as TBC1D4), a Rab guanosine triphosphatase-
activating protein (GAP), is currently recognized as the
most distal signaling step associated with insulin-mediated
glucose transport. In the basal state, the GAP guanosine
triphosphatase-activating domain of AS160 is hypothesized
to maintain Rab proteins in their inactive form, allowing
AS160 to colocalize and retain GLUT4 in intracellular
vesicles (6). In response to insulin, AS160 becomes phos-
phorylated on a number of Akt consensus sequences,
suppressing its GAP activity and resulting in the trans-
location of GLUT4 to the plasma membrane (6–9). The
functional importance of phosphorylated AS160 is evident
because a mutation in one or more phosphorylation sites
results in a reduction in insulin-stimulated GLUT4 trans-
location (9–11).
Insulin-stimulated AS160 phosphorylation may be im-
paired in insulin-resistant conditions because the insulin-
induced phosphorylation of AS160 is diminished with type
2 diabetes (12,13), polycystic ovary syndrome (14), and
fasting (4). Site-speciﬁc impairments in AS160 phosphor-
ylation (Ser-318, Ser-588, and Ser-751) have recently been
reported (13) with type 2 diabetes, suggesting that certain
phospho-speciﬁc sites may have greater implications in
insulin resistance. However, it is not evident whether the
site-speciﬁc regulation of AS160 is evident and consistent
across insulin-resistant conditions in human skeletal
muscle.
The inhibitory mechanisms regulating AS160 phosphor-
ylation remain obscure. In adipocytes, the transcriptional
coregulator, receptor interacting protein 140 (RIP140), has
been reported to interact with AS160, impeding the ability
of Akt to phosphorylate AS160 (15). It remains unknown
whether RIP140 impairs AS160 phosphorylation through a
similar mechanism in the skeletal muscle of insulin-resistant
individuals.
Endurance- (16–18) and strength-oriented (19,20) exer-
cise training can both improve insulin sensitivity and are
recommended as a means of intervention/prevention for
insulin resistance. However, data examining the effect of
exercise training on AS160 phosphorylation in human skel-
etal muscle is sparse. Some ﬁndings indicate that short-term
endurance training (3 weeks or less) was not sufﬁcient to
increase insulin-stimulated AS160 phosphorylation in young,
healthy (21), obese, nondiabetic (22), or diabetic individuals
(22). Unfortunately, conclusions from these studies (21,22)
are limited based on their use of the anti–phospho-Akt
substrate (PAS) antibody, which is thought to only rec-
ognize phosphorylation of AS160 on site Thr-642 (9,23).
The insulin resistance typically evident in middle- to older-
aged individuals is multifaceted and involves increases in
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overall and central adiposity and a reduction in cardiore-
spiratory ﬁtness as well as the effect(s) of chronological age
itself (1,24–31). The main objectives of the current study
were to 1) determine if the insulin resistance evident in
sedentary, middle- to older-aged individuals is associated
with impaired site-speciﬁc phosphorylation of AS160 in hu-
man skeletal muscle and 2) to determine whether strength-
and/or endurance-oriented exercise training could rescue
these impairments.
RESEARCH DESIGN AND METHODS
Experimental design. Study 1 used a cross-sectional design encompassing
younger to older individuals to determine if insulin action is associated with
a decrement in insulin signaling at the level of AS160. Study 2 determined if
a speciﬁc exercise training modality (endurance or strength training) could
effectively ameliorate the insulin resistance evident in sedentary, insulin-
resistant aged individuals by enhancing the most distal component of insulin
signal transduction. Figure 1 provides an overview of the experimental design.
Study 1—Cross-sectional study examining insulin action and distal
insulin signaling in human skeletal muscle
Participants. Speciﬁcally recruited for this study were 73 participants (41
women, 32 men) comprising a wide age range (18–84 years). Physical char-
acteristics of the subjects are provided in Table 1. All participants were
nonsmokers and participated in less than 1 h/week of organized physical ac-
tivity, as assessed by a standardized questionnaire. In an attempt to study a
representative population, inclusion required that a participant’s BMI be be-
tween the 25th and 75th percentile for his or her decade of age (32). Excluded
were individuals with heart disease, diabetes, endocrine, and/or metabolic
disorders, and those taking lipid-altering medication. Premenopausal women
were tested during the early follicular phase of the menstrual cycle (days 1–6).
Written informed consent was obtained, and the protocol was in accordance
of the Declaration of Helsinki and approved by the East Carolina University
Policy and Review Committee on Human Research.
Preliminary testing. Cardiorespiratory ﬁtness was measured with an in-
cremental, maximal treadmill test (33), with expired gases analyzed continu-
ously (TrueMax 2400; ParvoMedics, Sandy, UT) to determine VO2peak. Body
composition was measured by dual X-ray absorptiometry, and circumference
measurements of the waist, hip, and thigh were obtained with a spring-loaded
measuring tape.
Euglycemic-hyperinsulinemic clamp and muscle biopsies. Subjects
reported to the laboratory at 0700 after a 12-h overnight fast. A 2-h euglycemic-
hyperinsulinemic clampwas used to determine insulin action and elicit activation
of insulin signaling, as previously described (18,34). Brieﬂy, a primed insulin
(Humulin; Eli Lilly, Indianapolis, IN) infusion was performed for 10 min (starting
at 313 mU $ m22 $ min21), followed by a continuous infusion of insulin at a sub-
maximal dosage of 100 mU $ m22 $ min21. Blood samples were obtained every
5 min, centrifuged, and autoanalyzed for serum glucose (YSI 2300 STAT Plus
Glucose and Lactate Analyzer; YSI Inc., Yellow Springs, OH), and the glucose
infusion rate was adjusted as needed to maintain euglycemia. Blood plasma was
obtained every 10 min and stored at 280°C for the subsequent analysis of
plasma insulin (Access Immunoassay System; Beckman Coulter, Fullerton, CA).
A steady-state M-value was determined from the ﬁnal 20 min of the clamp (35).
A biopsy specimen was obtained from the vastus lateralis with the percu-
taneous muscle biopsy technique at baseline and at 60 min of the clamp. The
60-min time point was selected because we have previously reported that
components of insulin signal transduction (PI3-kinase activation and Akt Ser-
473 phosphorylation) appeared to be maximally activated at this time (36–38).
Tissue samples were immediately frozen in liquid nitrogen for subsequent
analyses.
Western blot and immunoprecipitation procedures. Skeletal muscle was
homogenized and protein content determined as previously described (39,40).
For Western blot analyses, muscle lysate (30–100 mg cellular protein) was
separated by SDS-PAGE, electrotransferred onto polyvinylidene diﬂuoride
membranes (Millipore, Billerica, MA), and probed overnight with Cell Sig-
naling (Beverly, MA) antibodies for PAS, phospho (p)Akt-Ser473 (recognizes
Akt-Ser472/473/474), AS160, Akt2, and cyclooxygenase IV (COXIV). Mem-
branes were also probed for pAS160-Thr642 (Millipore), pAS160-Ser666 (Mil-
lipore), pAS160-Ser588 (Symansis NZ Ltd, Timaru, New Zealand), GLUT4
(Afﬁnity BioReagents, Golden, CO), RIP140 (Santa Cruz Biotechnology, Santa
Cruz, CA), AS160 (Abcam, Cambridge, MA), and phospho-speciﬁc antibodies
for AS160 at sites Ser-318 and Ser-751, as previously described (23,41). Pro-
teins were visualized by horseradish peroxidase-conjugated IgG antibodies
and ECL SuperSignal (Pierce Biotechnology, Rockford, IL) exposed to X-ray
ﬁlm. All samples were normalized to a control sample on each gel, and
phosphorylation levels were additionally normalized to total protein after
membranes were stripped, as previously reported (41), and reprobed with the
corresponding antibody for total protein. For immunoprecipitation, lysates
(200 mg) were incubated at 4°C overnight with Cell Signaling Technology
antibodies for AS160 or Akt2 and for 3 h with protein A Sepharose beads (GE
Healthcare Biosciences Corp., Piscataway, NJ). Supernatant portions from
samples were removed and immunocomplexes analyzed with Western blotting.
Study 2—Effect of exercise training on distal insulin signaling
Participants. Of the 73 subjects recruited for the cross-sectional study, 45
volunteered for the experiment examining the effects of exercise training on
insulin signal transduction. Inclusion criteria required participants to be #35
years of age (young) or $55 years of age (aged). These individuals were then
randomized into a 12-week endurance- (n = 12 young, n = 11 aged) or strength-
training (n = 11 young, n = 11 aged) program. Two individuals were subsequently
excluded from the young, endurance group due to noncompliance (Fig. 1).
FIG. 1. Overview of experimental design. Young, £35 years (range 18–35); aged, ‡55 years (range 55–84).
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Experimental protocol. All subjects performed preliminary cardiovascular,
body composition, muscular strength, blood chemistry measurements, and a
3-day diet record, which were repeated during the ﬁnal week of training (Tables
2 and 3). The euglycemic-hyperinsulinemic clamp with muscle biopsies was
performed before exercise training and ;40 h after the ﬁnal exercise training
session (Fig. 1). All subjects completed a 24-h diet record the day before their
pretraining euglycemic-hyperinsulinemic clamp and were then asked to du-
plicate this diet the day before their post-training test.
Endurance training. The endurance-training program consisted of exer-
cising on a graded treadmill, stationary cycle, or elliptical trainer within a target
heart rate zone equivalent to 70–75% VO2peak for a total of 180 min/week (three
to four sessions per week). To ensure the appropriate workload during
training, a VO2peak test was performed after 6 weeks of training and workload
adjusted appropriately.
Strength training. Strength training consisted of upper and lower body
exercises, performed three times per week (;45 min/session). The upper body
exercises included chest press, latissimus pull down, seated row, triceps pull
down, and biceps curl. The lower body exercises included leg press, leg ex-
tension, and leg curl. Participants alternated between upper and lower body
exercises to minimize fatigue, with 60–90 s rest between sets, and performed
10–12 repetitions to failure. When a subject could complete 12 repetitions on
two consecutive occasions, resistance was increased by ;5%. Two sets were
completed for upper and lower body exercises during weeks 1–6, and during
weeks 7–12, a third set was added for lower body exercises.
Statistics. Analyses were performed using SPSS version 18.0 software (SPSS
Inc., Chicago, IL). Pearson correlation coefﬁcients and stepwise regression
were used to determine associations. Comparisons between young and aged
individuals before and after exercise training and under basal and insulin-
stimulated conditions were performed with repeated-measures ANOVA. Sig-
niﬁcantmain effects and interactions were further analyzed using unpaired (age
group) and paired (pre- vs. post-training and baseline vs. insulin-stimulated)
contrast-contrast comparisons. Data are presented as means 6 SEM. Statis-
tical signiﬁcance was deﬁned as P # 0.05.
RESULTS
Study 1—Cross-sectional study examining insulin
action and distal insulin signaling
Subject characteristics. The women exhibited a lower
body and fat-free mass, waist-to-hip ratio, VO2peak, and
elevated body and trunk fat percentage compared with the
TABLE 1
Participant characteristics for cross-sectional study
Men (n = 32) Women (n = 41)
Age 43.0 6 4.3 (19–84) 45.0 6 3.2 (18–76)
Mass (kg) 80.5 6 2.1 (62.7–105.9) 68.4 6 1.8 (52.3–97.7)*
BMI (kg/m2) 25.6 6 0.7 (19–34) 25.2 6 0.6 (18–35)
Body fat (%) 23.0 6 1.7 (8–39) 38.1 6 1.3 (16–53)*
Trunk fat (%) 27.2 6 2.1 (7.0–45.1) 39.1 6 1.5 (14.3–54.8)*
Fat-free mass (kg) 57.6 6 1.0 (48.3–72.4) 38.9 6 0.8 (30.5–51.8)*
Waist-to-hip ratio 0.86 6 0.02 (0.76–1.04) 0.76 6 0.01 (0.66–0.92)*
VO2peak (mL/kg/min) 34.8 6 2.1 (12.6–58.7) 26.0 6 1.2 (12.6–42.2)*
Fasting plasma glucose (mg/dL) 89.2 6 1.4 (73–105) 88.1 6 1.5 (71–118)
Fasting plasma insulin (mIU/mL) 5.5 6 0.6 (1.5–14.4) 5.9 6 0.8 (1.5–29.5)
Data are presented mean 6 SEM (range). *P , 0.005 vs. men.
TABLE 2
Changes in characteristics of young and aged individuals before and after endurance training
Young (n 5 10) Aged (n 5 11)
Variable Pretraining Post-training Pretraining Post-training





M-value (mg/kg/min) 7.9 6 0.8 9.8 6 0.7* 5.7 6 0.5† 6.3 6 0.6†*
Body composition
Mass (kg) 69.8 6 2.2 69.2 6 2.5 80.3 6 4.2† 80.4 6 4.4†
BMI (kg/m2) 23.8 6 0.9 23.5 6 0.7 27.9 6 1.1† 27.9 6 1.2†
Body fat (%) 25.5 6 3.7 23.6 6 3.5* 38.4 6 2.4† 37.3 6 2.6†*
Lean body mass (kg) 47.4 6 2.8 48.8 6 3.1* 47.3 6 3.3 47.8 6 3.3*
Thigh circumference (cm) 48.7 6 1.6 48.3 6 1.5 50.1 6 1.5 50.3 6 1.8
Waist-to-hip ratio 0.78 6 0.02 0.77 6 0.02 0.88 6 0.04† 0.87 6 0.03†
Performance
VO2peak (mL/kg/min) 35.0 6 1.6 41.7 6 1.3* 19.9 6 1.2† 22.3 6 1.5†*
Peak isokinetic leg extension (N) 599 6 72 612 6 57 449 6 47 468 6 35
Peak isokinetic leg ﬂexion (N) 396 6 49 429 6 50 252 6 32† 272 6 41†
1-RM leg press (kg) 119 6 9 121 6 10 96 6 10 99 6 12
1-RM chest press (kg) 49 6 6 54 6 8* 33 6 3 37 6 8*
Fasting blood chemistry
Glucose (mg/dL) 84.3 6 2.4 78.6 6 2.8* 91.6 6 3.1 89.1 6 4.0*
Insulin (IU/mL) 4.6 6 1.0 3.7 6 1.1* 7.3 6 1.2 4.3 6 1.1*
Data are presented mean6 SEM (range) or as indicated. Statistics performed on absolute values. †P, 0.05 age main effect. *P, 0.05 training
main effect.
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men (Table 1). Univariate correlations indicated that mass
(r = 0.26, P , 0.05), BMI (r = 0.45, P , 0.001), body fat
percentage (r = 0.49, P , 0.001), trunk fat (r = 0.53, P ,
0.001), and waist-to-hip ratio (r = 0.50, P , 0.001) in-
creased with age. Relative Vo2peak (mL/kg/min) declined
with age (r = 20.78, P , 0.001), whereas fasting blood
glucose (r = 0.40, P , 0.001) increased with age.
Insulin action and AS160 phosphorylation. The
euglycemic-hyperinsulinemic clamp increased (P , 0.001)
plasma insulin concentration from fasting (5.06 0.4 mIU/mL)
to 160 6 6 mIU/mL. Whole-body insulin action (M-value)
declined with age (r = 20.52, P , 0.001; Supplementary
Fig. 1). Sex had no effect on this relationship; therefore,
data from men and women were combined for subsequent
analyses.
Stepwise linear regression analysis was used to de-
termine variables (age, body weight, BMI, percentage body
fat, percentage trunk fat, waist-to-hip ratio, VO2peak, and
fasting insulin) that independently predicted insulin action.
Age and BMI were both independent predictors of insulin
action (total adjusted R2 = 0.44, P , 0.001).
Insulin infusion increased (P , 0.001) phosphorylation
of all ﬁve AS160 phospho-speciﬁc sites and PAS by ;2- to
8-fold and of Akt2 Ser-473 by;30-fold. As presented in Fig.
2, whole-body insulin action was positively related with
AS160 phosphorylation when determined by PAS (r = 0.33,
P , 0.01) and on sites Ser-588 (r = 0.34, P , 0.05), Thr-642
(r = 0.33, P , 0.05), and Ser-666 (r = 0.32, P , 0.05). In-
sulin action was not related to AS160 phosphorylation of
Ser-751 or Ser-318 sites or with Akt2 Ser-473 phosphory-
lation (n = 61, r = 0.15, P . 0.05).
Stepwise linear regression analysis was used to de-
termine variables (age, BMI, percentage body fat, percent-
age trunk fat, waist-to-hip ratio, VO2peak, fasting glucose,
and insulin) that independently predicted insulin-induced
phosphorylation of AS160. Chronological age was the sole
predictor of insulin-induced phosphorylation of AS160 Ser-
666 (R2 = 0.12, P, 0.05). Body fat was determined to be the
best predictor of insulin-induced phosphorylation of AS160
PAS (R2 = 0.12, P, 0.01) and AS160 Ser-588 (R2 = 0.10, P,
0.05), whereas fasting insulin was determined to be the best
predictor of insulin-induced phosphorylation of AS160
Thr-642 (R2 = 0.10, P , 0.05).
Age was not related to the ability of insulin to phos-
phorylate Akt2 Ser-473 (r = 20.18, P . 0.05; data not
shown). Chronological age was negatively related to the
insulin-stimulated phosphorylation of AS160 determined
by PAS (r = 20.25, P , 0.05) and sites Ser-588 (r = 20.28,
P , 0.05), Thr-642 (r = 20.28, P , 0.05), and Ser-666 (r =
20.30, P , 0.05; Supplementary Fig. 2). Basal phosphor-
ylation levels of AS160 Thr-642 increased with age (r =
0.30, P, 0.05; data not shown). Age had no other effect on
AS160 basal phosphorylation levels or protein content.
GLUT4 protein content demonstrated a trend for a nega-
tive relationship with age (r = 20.24, P = 0.06; Supple-
mentary Fig. 2).
RIP140. Total RIP140 protein content was determined
in 19 young (range 18–35 years) and 20 insulin-resistant
aged (range 57–84 years) individuals, and the amount
of RIP140 complexed with AS160 was determined in a
subset of 11 young (range 18–26 years) and 9 insulin-
resistant aged (range 56–82 years) individuals. There
were no differences in total RIP140 protein content be-
tween young and aged individuals (Fig. 3A), but insulin-
resistant aged individuals had a higher amount of RIP140
complexed with AS160 (P, 0.03, Fig. 3B) compared with
their young counterparts. As presented in Fig. 3C, the
amount of RIP140 complexed with AS160 exhibited
a trend (r = 20.42, P = 0.06) to be negatively related to
insulin action.
TABLE 3
Changes in characteristics of young and aged individuals before and after strength training
Young (n 5 11) Aged (n 5 11)
Variable Pretraining Post-training Pretraining Post-training





M-value (mg/kg/min) 9.4 6 0.8 10.8 6 1.0* 6.1 6 0.7† 6.9 6 0.7†*
Body composition
Mass (kg) 71.8 6 3.5 73.3 6 3.3* 76.4 6 3.7 76.7 6 3.7*
BMI (kg/m2) 23.5 6 0.7 25.3 6 1.2 26.8 6 1.1 26.9 6 1.1
Body fat (%) 22.9 6 3.7 22.1 6 3.7 36.9 6 2.6† 36.2 6 2.7†
Lean body mass (kg) 53.0 6 3.6 53.9 6 3.4* 45.2 6 3.3 46.2 6 3.3*
Thigh circumference (cm) 50.9 6 1.1 51.4 6 1.0 49.0 6 1.1 48.5 6 1.5
Waist-to-hip ratio 0.76 6 0.02 0.75 6 0.02 0.87 6 0.03† 0.87 6 0.03†
Performance
VO2peak (mL/kg/min) 38.2 6 2.1 41.5 6 2.8* 20.6 6 1.8† 21.7 6 1.9†*
Peak isokinetic leg extension (N) 718 6 70 874 6 73* 500 6 43† 534 6 36†
Peak isokinetic leg ﬂexion (N) 413 6 38 530 6 41* 292 6 24† 331 6 29†*
1-RM leg press (kg) 121 6 11 148 6 17* 81 6 12† 103 6 9†*
1-RM chest press (kg) 54 6 10 58 6 9* 31 6 5 37 6 5*
Fasting blood chemistry
Glucose (mg/dL) 84.1 6 2.5 80.1 6 2.8* 92.3 6 2.8 89.5 6 2.3*
Insulin (IU/mL) 4.8 6 1.1 3.7 6 0.9* 5.1 6 1.1 3.7 6 1.0*
Data are presented mean6 SEM (range) or as indicated. Statistics performed on absolute values. †P, 0.05 age main effect. *P, 0.05 training
main effect.
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Study 2—Effects of exercise training on insulin
action and distal insulin signaling
General adaptations to exercise training. Differences
in whole-body insulin action (M-value), body composition,
VO2peak, and fasting blood chemistries were evident be-
tween the young and aged groups before initiating the
12 weeks of exercise training (Tables 2 and 3). With en-
durance training, there was a reduction in body fat
and an increase in lean body mass, which resulted in no
change in overall body mass (Table 2). Endurance train-
ing also increased insulin action (M-value), VO2peak, and
1-repetition maximum (RM) chest press and decreased fasting
plasma glucose and insulin (Table 2). Strength training
increased 1-RM leg press, 1-RM chest press, and peak
isokinetic leg ﬂexion strength in young and insulin-
resistant aged participants and also increased lean and
total body mass and VO2peak (Table 3). Insulin action also
increased irrespective of group, whereas fasting plasma
glucose and insulin concentrations decreased in response
to strength training (Table 3). Skeletal muscle COXIV
protein, a marker of mitochondrial content, increased in
response to endurance training (;30%) but not with
strength training (Supplementary Fig. 3). Analysis of 3-day
diet records revealed no signiﬁcant changes in caloric
FIG. 2. Relationships among insulin-stimulated phosphorylation levels of skeletal muscle AS160 PAS (n = 67) (A), Ser-588 (n = 56) (B), Thr-642
(n = 57) (C), Ser-666 (n = 52) (D), Ser-751 (n = 61) (E), and Ser-318 (n = 60) (F) with whole-body insulin action. A: For PAS, AS160 was
immunoprecipitated and then blotted with the PAS antibody. B–F: All other blots used phospho-speciﬁc antibodies. Values, in AU were normalized
to a control sample run on each blot and then presented relative to total AS160 protein. AU, arbitrary units.
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intake (total, protein, carbohydrate, and fat) during the
training period.
AS160 phosphorylation. In agreement with the corre-
lation analyses (Supplementary Fig. 1), reductions in
insulin-stimulated Ser-588, Thr-642, Ser-666 (P, 0.05), and
PAS (P = 0.06) phosphorylation were evident in insulin-
resistant aged individuals in the pretraining, sedentary
state (Fig. 4). Endurance training increased insulin-
stimulated AS160 phosphorylation of PAS by ;60% in
young and ;75% in insulin-resistant aged individuals (P ,
0.05, Fig. 5A), whereas AS160 Ser-588 phosphorylation
increased ;25% in both groups (P , 0.05, Fig. 5B). There
was a signiﬁcant interaction (P , 0.05) for AS160 Thr-642
in response to endurance training as the aged individuals
increased AS160 Thr-642 phosphorylation by ;57% (P ,
0.05, Fig. 5C), whereas no signiﬁcant changes were ob-
served in the young individuals. There was a tendency (P =
0.07) for insulin-stimulated Ser-666 phosphorylation to in-
crease with endurance training in the aged subjects
(Fig. 5D). No changes with endurance training were evi-
dent in insulin-stimulated Ser-751 and Ser-318 (data not
shown). Strength training increased insulin-stimulated
AS160 phosphorylation of PAS by ;75% (P, 0.01, Fig. 6A )
in both groups, whereas insulin-stimulated Thr-642 phos-
phorylation increased by ;33% and ;73% in young and
aged individuals (P , 0.05, Fig. 6C,), respectively. In
addition, strength training increased insulin-stimulated
Ser-666 phosphorylation of AS160 by ;100% (Fig. 6D) in
the insulin-resistant aged group. There were no changes in
Ser-588 (Fig. 6B), Ser-751 (data not shown), or Ser-318
(data not shown) with strength training.
Exercise training had no effect on AS160 protein content
(data not shown). Basal phosphorylation levels of PAS
were signiﬁcantly reduced (;50%, P, 0.01) in response to
strength training, which contributed to the signiﬁcant
training effect (Fig. 6A). Exercise training had no other
effect on basal AS160 phosphorylation levels. Endurance
training increased GLUT4 (;10% for young and ;15% for
aged, P , 0.05; Supplementary Fig. 4), whereas strength
training had no effect. Multiple regression analysis in-
dicated that exercise-induced changes in phosphorylation
of PAS, Ser-588, Thr-642, and Ser-666 accounted for 28%
of the variance in the improvement in insulin action
(P , 0.05).
Before exercise training, Akt2 protein levels did not
differ between the groups (data not shown). Endurance
training increased Akt2 protein levels by ;60% in the
young group (P , 0.01), with a similar trend in the aged
individuals (P = 0.08). In response to strength training,
Akt2 protein levels demonstrated a trend for an increase
(P = 0.08). Neither age nor exercise training had an effect
on Akt2 Ser-473 phosphorylation when normalized to
protein content (Supplementary Fig. 5).
DISCUSSION
In the current study, we show for the ﬁrst time that insulin-
stimulated AS160 phosphorylation, measured by the PAS
antibody, and speciﬁc phosphorylation at sites Ser-588,
Thr-642, and Ser-666 are impaired in human skeletal
muscle in conjunction with the decrement in insulin action
typical with advancing age and a sedentary lifestyle (Figs.
2 and 4). Impaired insulin-mediated AS160 phosphory-
lation has been reported in other insulin-resistant con-
ditions, including type 2 diabetes (12) and polycystic ovary
syndrome (14), using the PAS antibody. The PAS antibody
FIG. 3. Quantiﬁcation of total RIP140 (A) in the skeletal muscle of
young (n = 19, 18–35 years) vs. aged (n = 20, 57–84 years) individuals
and the quantiﬁcation of RIP140/AS160 complex (B) in the skeletal
muscle of young (n = 11, 18–26 years) vs. aged (n = 9, 57–82 years)
individuals.C: Relationship of RIP140/AS160 complex with insulin action
(n = 20). B and C: For determination of RIP140/AS160 complex, whole-
cell muscle lysates were immunoprecipitated (IP) with AS160 and
immunoblotted (IB) with RIP140 (complex formation) and AS160 (total
AS160 immunoprecipitated). Values are in AU and data expressed as
mean 6 SEM. AU, arbitrary units; N.S., nonsigniﬁcant. *P £ 0.05.
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may recognize multiple phosphorylation sites on AS160;
however, current research suggests this antibody is limited
to only recognizing AS160 phosphorylation on Thr-642
(9,23). More recently, site-speciﬁc impairments were
identiﬁed in patients with type 2 diabetes (Ser-318, Ser-588,
and Ser-751) (13) and in healthy individuals after fasting-
induced insulin resistance (Ser-588 and Ser-751) (4). The
current data (Figs. 2 and 4), in combination with other data
(4,13), provide the important information that an impair-
ment in Ser-588 phosphorylation appears to be consistent
in human skeletal muscle across conditions inducing in-
sulin resistance. In contrast, other AS160 sites demon-
strate differential phosphorylation patterns, possibly as
a product of kinases and phosphatases being regulated by
the severity or the pathology of insulin resistance. Col-
lectively, these ﬁndings show that conditions of whole-
body insulin resistance are linked with site-speciﬁc
impairments in AS160 and provide novel insight into
a signaling impairment located distally in the insulin-
signaling cascade.
In an effort to investigate cellular mechanisms that
could contribute to the impaired AS160 phosphorylation,
we examined RIP140 expression and its association with
AS160. In adipocytes, the binding of RIP140 to AS160
results in reduced glucose uptake, likely as a result of
RIP140 impeding the ability of Akt to inactivate GAP
activity on AS160 (15). The current ﬁnding that insulin-
resistant aged individuals had a higher amount of RIP140
complexed with AS160 (Fig. 3B) provides novel evidence
that the impairment in AS160 phosphorylation may be
linked to the association of AS160 with RIP140, which in
turn induces insulin resistance (Fig. 3C).
In an attempt to gain an understanding of factors that
may regulate site-speciﬁc phosphorylation on AS160, we
performed regression analyses using variables linked with
insulin action. Body fat percentage was the best predictor
of Ser-588 phosphorylation, whereas basal plasma insulin
levels proved to be the best predictors of Thr-642 phos-
phorylation, suggesting these phosphorylation sites may
be differentially regulated. In agreement with these ﬁnd-
ings, in vitro experiments in adipocytes demonstrated
that insulin-stimulated phosphorylation of Thr-642 occurs
much more rapidly than Ser-588, and hierarchical clus-
tering analysis revealed that Thr-642 did not cluster with
Ser-588 (42). Taken together, this information provides
insight into potential regulatory mechanisms of AS160
phosphorylation; however, we acknowledge that re-
gression analyses only imply relationships and that ad-
ditional variables not measured in the current study may
also play a role in the regulation of site-speciﬁc AS160
phosphorylation.
Of the two Akt isoforms expressed in skeletal muscle
(Akt1 and Akt2), Akt2 is considered crucial for glucose
uptake in skeletal muscle (43). In relation to upstream
signaling of AS160, we recognize that phosphorylation of
both Akt Ser-473 and Thr-308 is required for the full acti-
vation of Akt; however, the current study was limited to
Akt2 Ser-473 based on results in human skeletal muscle
indicating that insulin-stimulated Akt2-Ser473 phosphory-
lation (as opposed to Akt-Thr308) was closely related to
AS160-PAS phosphorylation and glucose uptake (43).
Insulin-stimulated Akt2-Ser473 phosphorylation was not as-
sociated with insulin-resistant aged individuals in the cur-
rent study; however, Sharma et al. (44), recently reported
reduced insulin-stimulated Akt2-Thr308 phosphorylation
in the soleus of aged (25-month) compared with adult
(9-month) rats; therefore, we cannot conclusively state
that all Akt sites were preserved with insulin resistance.
Exercise training has long been recognized as a method
to improve insulin action (16–19) (Tables 2 and 3). The
effect of exercise training on insulin-stimulated AS160
phosphorylation has been sparsely addressed, particularly
FIG. 4. Fold change (insulin stimulated over basal) in AS160 PAS (A), Ser-588 (B), Thr-642 (C), and Ser-666 (D) in young (n = 18–21, age range
18–35 years, white bars) and aged (n = 19–22, age range 55–84 years, black bars) individuals. Data are mean 6 SEM. *P < 0.05.
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in regards to phospho-speciﬁc sites. Previous research
reported that insulin-mediated AS160 phosphorylation in-
creased in healthy young men after 3 weeks of one-legged
endurance-oriented exercise training; however, these
effects were negated when phosphorylation was normal-
ized to AS160 protein content (21). In addition, O’Gorman
et al. (22) reported that short-term endurance training
(7 days) was not sufﬁcient to increase insulin-stimulated
AS160 phosphorylation in obese, nondiabetic, or diabetic
individuals. However, conclusions from these studies
(21,22) are limited based on the use of the PAS antibody.
A key ﬁnding in the current study was that decrements
in speciﬁc insulin-stimulated AS160 phosphorylation sites
were improved with exercise training (Figs. 5 and 6), with
the exception of AS160 Ser-588 (Fig. 6B), which did not
appear to be responsive to strength training (Fig. 6B). Vind
et al. (13) previously reported increased insulin-induced
AS160 phosphorylation on Ser-588 in type 2 diabetic
patients, but not in nondiabetic control subjects, in re-
sponse to 10 weeks of endurance training, suggesting that
this site may be particularly responsive to endur-
ance exercise in insulin-resistant populations. From our
FIG. 5. Phosphorylation levels of skeletal muscle AS160 PAS (n = 10, young; n = 11, aged) (A), Ser-588 (n = 10, young; n = 10, aged) (B), Thr-642
(n = 9, young; n = 9, aged) (C), and Ser-666 (n = 9, young; n = 8, aged) (D) in response to insulin before and after 12 weeks of endurance training in
young (age 24.4 6 1.6, range 18–34 years, white bars) and aged (age 69.0 6 2.2, range 57–84 years, black bars) individuals. Data are presented as
fold change in phosphorylation levels normalized to total AS160 protein levels. The line above the bars represents the main effect for age (short
bar) or training (long bar). Data are mean 6 SEM. E: Representative blots using AS160 phospho-speciﬁc antibodies and total protein in young and
aged individuals under noninsulin (B) and insulin-stimulated (I) conditions. For PAS, AS160 was initially immunoprecipitated and then blotted
with the PAS antibody. *P < 0.05 vs. pretraining. †P < 0.05 vs. young at that comparable time.
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cross-sectional data, we determined that body fat per-
centage was the best predictor of AS160 Ser-588 phos-
phorylation. Body fat percentage was reduced in response
to endurance, but not strength training, which could ex-
plain why improvements in Ser-588 phosphorylation were
only evident with this training modality. Protein kinase Cz
(PKCz) activity has been hypothesized to regulate AS160
Ser-588 phosphorylation (42), and endurance training has
been reported to increase skeletal muscle PKCz activity
(45). Although speculative, it is plausible to suggest that
our endurance-training program improved PKCz activity,
which could in part explain improvements in insulin-
stimulated AS160 Ser-588 phosphorylation.
Both modes increased PAS, Thr-642, and Ser-666 (P =
0.07 with endurance training) phosphorylation in the aged
group, indicating the effectiveness of exercise in treating
insulin resistance. The clinical relevance of our ﬁndings is
that either endurance or strength training appears to im-
prove insulin action through similar mechanisms in re-
lation to insulin signaling at the level of AS160. This ﬁnding
may provide relevant information in terms of therapeutic
treatments for insulin-resistant conditions.
FIG. 6. Phosphorylation levels of skeletal muscle AS160 PAS (n = 11, young; n = 11, aged) (A), Ser-588 (n = 11, young; n = 11, aged) (B), Thr-642
(n = 10, young; n = 10 aged) (C), and Ser-666 (n = 10, young; n = 10, aged) (D) in response to insulin before and after 12 weeks of strength training
in young (23.6 6 1.5 years of age, range 20–35 years, white bars) and aged (69.3 6 2.7 years, range 55–82 years, black bars) individuals. Data are
presented as fold change in phosphorylation levels normalized to total AS160 protein levels. The line above the bars represents the main effect for
age (short bar) or training (long bar). Data are mean 6 SEM. E: Representative blots using AS160 phospho-speciﬁc antibodies and total protein in
young and aged individuals under noninsulin (B) and insulin-stimulated (I) conditions. For PAS, AS160 was initially immunoprecipitated and then
blotted with the PAS antibody. *P < 0.05 vs. pretraining. †P < 0.05 vs. young at that comparable time.
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Consistent with other studies examining human subjects
over a wide life span (1,24,26,30,46), our data demon-
strated that whole-body insulin action declined with age
(Supplementary Fig. 1). The nature of this age-related in-
sulin resistance has been well-studied and likely involves
a number of contributing factors, including increased ab-
dominal adiposity (30), declining cardiorespiratory ﬁtness
(29,31), and chronological age itself (29), all of which were
evident in our population (Table 1). Despite reports sug-
gesting that the effect of chronological age is negated
when adjusting for BMI (26), adiposity (27), or physical
inactivity (28), our data indicate that chronological age
was an independent predictor of whole-body insulin ac-
tion, which is in agreement with the ﬁndings of at least one
other study (29).
A limitation of the current study was that muscle ﬁber
typing was not performed. Animal studies have reported
greater age-related impairments in glucose uptake in slow-
twitch compared with fast-twitch muscle (44,47), despite
the apparent preservation of type I ﬁber cross-sectional
area with aging (48). Likewise, 12 weeks of endurance or
strength training has been associated with increases in
type I (49) and type II (50) ﬁber area, respectively, in-
dependent of age (48,49). Therefore, the age- or exercise-
related differences in AS160 phosphorylation in our current
study could possibly have been inﬂuenced by changes in
muscle ﬁber type. In addition, despite previous research
suggesting maximal AS160 phosphorylation occurs at 60
min of an euglycemic-hyperinsulinemic clamp (36,38), we
cannot exclude the possibility that the rate of site-speciﬁc
AS160 phosphorylation was inﬂuenced by either age and/or
exercise training.
In conclusion, the ﬁndings of the current study indicate
for the ﬁrst time that deﬁcits in whole-body insulin action
evident with the aging process and a sedentary lifestyle are
associated with reduced insulin-stimulated phosphoryla-
tion of speciﬁc AS160 sites (Thr-642, Ser-588, Ser-666, and
PAS). With respect to intervention/prevention, 12 weeks of
endurance- or strength-oriented exercise training increased
whole-body insulin action and rescued impairments in AS160
phosphorylation. Collectively, these ﬁndings suggest that
decrements in the ability of insulin to phosphorylate spe-
ciﬁc sites on skeletal muscle AS160 contribute to insulin
resistance and that exercise training is an effective treat-
ment option to counteract these impairments.
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